QLINEA Stock Overview
Engages in the development of instruments and consumables for infection diagnostics in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Q-linea AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.56 |
| 52 Week High | SEK 8.36 |
| 52 Week Low | SEK 1.95 |
| Beta | 0.99 |
| 11 Month Change | -10.11% |
| 3 Month Change | 39.14% |
| 1 Year Change | -49.79% |
| 33 Year Change | -97.68% |
| 5 Year Change | -94.36% |
| Change since IPO | -94.72% |
Recent News & Updates
Recent updates
Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely
Dec 31
Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?
May 07Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans
Jan 11We're Hopeful That Q-linea (STO:QLINEA) Will Use Its Cash Wisely
Feb 17
Do Institutions Own Q-linea AB (publ) (STO:QLINEA) Shares?
Dec 26Shareholder Returns
| QLINEA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 0.7% | 0.6% | 1.0% |
| 1Y | -49.8% | 3.0% | 18.4% |
Return vs Industry: QLINEA underperformed the Swedish Medical Equipment industry which returned 1.6% over the past year.
Return vs Market: QLINEA underperformed the Swedish Market which returned 14.5% over the past year.
Price Volatility
| QLINEA volatility | |
|---|---|
| QLINEA Average Weekly Movement | 16.3% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: QLINEA's share price has been volatile over the past 3 months.
Volatility Over Time: QLINEA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 99 | Stuart Gander | qlinea.com |
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom. The company offers ASTar, an antibiotic susceptibility testing system used for positive blood cultures; and in vitro diagnostics systems for infectious diseases. It serves healthcare providers.
Q-linea AB (publ) Fundamentals Summary
| QLINEA fundamental statistics | |
|---|---|
| Market cap | SEK 415.36m |
| Earnings (TTM) | -SEK 224.61m |
| Revenue (TTM) | SEK 7.13m |
58.3x
P/S Ratio-1.8x
P/E RatioIs QLINEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QLINEA income statement (TTM) | |
|---|---|
| Revenue | SEK 7.13m |
| Cost of Revenue | SEK 7.34m |
| Gross Profit | -SEK 207.00k |
| Other Expenses | SEK 224.40m |
| Earnings | -SEK 224.61m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | -1.92 |
| Gross Margin | -2.90% |
| Net Profit Margin | -3,150.61% |
| Debt/Equity Ratio | 60.9% |
How did QLINEA perform over the long term?
See historical performance and comparison